Pushing the Envelope: Developing Bi-Specific ADCs Using a Novel GlycOBI™ Platform
Time: 4:30 pm
day: Day Two
Details:
- Reviewing the advantages of Dual Targeting: Enhancing efficacy by targeting multiple tumor proteins simultaneously, combats resistance with varied mechanisms of action, and broadens the target patient populations
- Considering the benefits and Target Selection: Selecting the optimal targets and ideal formats remains complex, requiring precise identification of tumor-specific proteins for effective dual targeting
- An overview of the benefits of GlycOBI™ Platform: Producing homogenous ADCs without genetic modification, enhancing stability and anti-tumor activity with hydrophilic linkers, and simplifying the Chemistry, Manufacturing, and Controls (CMC) process
